Exegenesis Bio and Modalis Therapeutics have entered a research partnership and licence agreement to progress MDL-201, a therapeutic candidate for Duchenne muscular dystrophy (DMD).
ST266 is a novel “secretome,” cell-free platform biologic, containing hundreds of proteins and other biological factors involved in cellular healing. For delivery to the optic nerve and brain,
“Vitiligo is a challenging and life-altering disease further complicated by the lack of effective treatment options available to physicians and their patients,” said Jim Lee, M.D., Ph.D., Group
“With the addition of this IND enabled program to our pipeline, we advance our agenda to bring innovative treatments to patients with fibrotic disorders,” stated Wendye Robbins, M.D.,
The phase 3 global, double-blind, placebo-controlled, randomised-withdrawal, multicentre study has assessed the efficacy and safety of JZP-258 in the treatment of cataplexy and excessive daytime sleepiness (EDS) in
The round was co-led by NanoDimension and Qiming Venture Partners USA, and included new investors Clough Capital, Aju IB, Korys Merieux, Kaitai Capital, Industrial Investors, Nawton Limited and
“Fast track designation is an important milestone for our retinal disease platform, and promising news for PVR patients,” said Todd C. Brady, M.D., Ph.D., President and Chief Executive
Invented and developed by Zealand Pharma, dasiglucagon is a potential first-in-class soluble glucagon analogue with a unique stability profile in a ready-to-use aqueous solution. Dasiglucagon is being developed
Results from the study will be presented at the MDS International Congress in Nice, France, September 22-26, 2019 as poster #13705 and poster #13711. ENGAGE is the first
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.
